Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lab Industry, Cancer Groups Want Expanded Medicare Coverage Of NGS For Advanced Cancers

Executive Summary

While device firms that create lab test kits, clinical laboratories and cancer medicine groups supported US Centers for Medicare and Medicaid Services' proposed national coverage determination for use of next generation sequencing (NGS) for advanced cancer tests in recent comments, they want the agency to modify its approach to the NCD in one way or another and, in many cases, expand it. A final coverage decision is imminent.

You may also be interested in...



US Medicare Agency Proposes Expanding Coverage Of Next-Generation Sequencing For Advanced Cancers

There is sufficient evidence to expand coverage of next-generation sequencing (NGS) as a diagnostic test for ovarian, breast or other advanced cancers if certain criteria are met, the Centers for Medicare and Medicaid Services wrote in a 30 October proposed decision memo.

US CMS Opens Medicare National Coverage Analysis For NGS Germline Mutation Tests

The CMS opened a national coverage analysis tracking sheet on 29 April to reconsider evidence for next-generation sequencing tests of germline mutations. These assays identify beneficiaries with hereditary cancer who may benefit from targeted treatments based on the tests’ conclusions about carcinogenic genetic mutations passed on by patients’ parents.

Medicare Finalizes NGS Test Coverage For Advanced Cancers, Drops Evidence-Collection Provision

The US Centers for Medicare and Medicaid Services said on March 16 that it will cover next-generation sequencing diagnostic laboratory tests for advanced cancers, broadening its final determination to cover use in relapsed, refractory and stage III cancers, while dropping "coverage with evidence development" conditions.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT122274

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel